ReviewCancers2020
Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-PArtial Tumor Irradiation Targeting HYpoxic Segment (SBRT-PATHY).
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- The future is not always uniform: rethinking radiotherapy through spatial fractionation.Nature reviews. Clinical oncology · 2026Review
- SFRT alleviates symptoms associated with bulky advanced cancer: a retrospective single-center cohort analysis.Frontiers in oncology · 2026Article
- Immunomodulatory Effects of High-Dose Irradiation Regimens in Renal Cell Carcinoma: Insights from an In Vitro Model with Human Peripheral Blood Mononuclear Cell.Biomedicines · 2025Article
- Radiotherapy-induced alterations in tumor microenvironment: metabolism and immunity.Frontiers in cell and developmental biology · 2025Review
- Case Report: Early experience with hypoxia-targeted SBRT-based partial tumor irradiation in large and bulky tumors.Frontiers in oncology · 2025Article
- From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy.Frontiers in immunology · 2025Review
- Advances in radiotherapy enhancing the efficacy of immune checkpoint inhibitors in malignant.Frontiers in oncology · 2025Review
- Reduced irradiation exposure areas enhanced anti-tumor effect by inducing DNA damage and preserving lymphocytes.Molecular medicine (Cambridge, Mass.) · 2024Article
- FAM83H regulated by glis3 promotes triple-negative breast cancer tumorigenesis and activates the NF-κB signaling pathway.Journal of molecular histology · 2024Article
- Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade.Nature communications · 2024Article
- Particle Beam Radiobiology Status and Challenges: A PTCOG Radiobiology Subcommittee Report.International journal of particle therapy · 2024Review
- Spatially Fractionated Radiotherapy in the Era of Immunotherapy.Seminars in radiation oncology · 2024Review
- Computational Approach for Spatially Fractionated Radiation Therapy (SFRT) and Immunological Response in Precision Radiation Therapy.Journal of personalized medicine · 2024Article
- Stereotactic central/core ablative radiation therapy: results of a phase I study of a novel strategy to treat bulky tumor.Frontiers in oncology · 2024Article
- Combining spatially fractionated radiation therapy (SFRT) and immunotherapy opens new rays of hope for enhancing therapeutic ratio.Clinical and translational radiation oncology · 2024Review
- Immune Priming with Spatially Fractionated Radiation Therapy.Current oncology reports · 2023Review
- Review
- Application of radiomics in lung immuno-oncology.Precision radiation oncology · 2023Review
- Novel unconventional radiotherapy techniques: Current status and future perspectives - Report from the 2nd international radiation oncology online seminar.Clinical and translational radiation oncology · 2023Article
- Overexpression of POU3F2 promotes radioresistance in triple-negative breast cancer via Akt pathway activation.Breast cancer research and treatment · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation-induced immune-mediated abscopal effects (AE) of conventional radiotherapy are very rare. Whole-tumor irradiation leads to lymphopenia due to killing of immune cells in the tumor microenvironment, resulting in immunosuppression and weak abscopal potential. This limitation may be overcome by partial tumor irradiation sparing the peritumoral immune-environment, and consequent shifting of immune-suppressive to immune-stimulatory effect. This would improve the radiation-directed tumor cell killing, adding to it a component of immune-mediated killing. Our preclinical findings showed that the high-single-dose irradiation of hypoxic tumor cells generates a stronger bystander effect (BE) and AE than the normoxic cells, suggesting their higher "immunogenic potential". This led to the development of a novel Stereotactic Body RadioTherapy (SBRT)-based PArtial Tumor irradiation targeting HYpoxic segment (SBRT-PATHY) for induction of the immune-mediated BE and AE. Encouraging SBRT-PATHY-clinical outcomes, together with immunohistochemical and gene-expression analyses of surgically removed abscopal-tumor sites, suggested that delivery of the high-dose radiation to the partial (hypoxic) tumor volume, with optimal timing based on the homeostatic fluctuation of the immune response and sparing the peritumoral immune-environment, would significantly enhance the immune-mediated anti-tumor effects. This review discusses the current evidence on the safety and efficacy of SBRT-PATHY in the treatment of unresectable hypoxic bulky tumors and its bystander and abscopal immunomodulatory potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.